Revumenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Relapsed/Refractory Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Company guidance: data expected 4Q26 (Syndax, 2 Nov 2026). “New revumenib data expected in 4Q26 from clinical trials and real-world studies spanning the acute leukemia treatment continuum and multiple genetic subtypes –” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Acute Myeloid Leukemia
Phase 2/3 (1)
Relapsed/Refractory Acute Myeloid Leukemia
NCT03013998 · Beat AML, LLC
2016-11 – 2032-12 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
What this study did
Phase 2 (7)
Acute Lymphoblastic Leukemia
NCT07636564 · SWOG Cancer Research Network
2026-10-14 – 2032-04-16 · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
What this study did
Acute Myeloid Leukemia
NCT07563010 · Center for International Blood and Marrow Transplant Research
2026-12 – 2031-06 · Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
What this study did
NCT07686107 · Therapeutic Advances in Childhood Leukemia Consortium
2026-08-31 – 2030-12-31 · Leukemia, Myeloid, Acute
What this study did
NCT07605949 · UNC Lineberger Comprehensive Cancer Center
2026-12 – 2028-07 · Leukemia Acute Myeloid
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT07949370 · Dana-Farber Cancer Institute
2027-03-06 – 2030-07-31 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT05761171 · Children's Oncology Group
2024-01-08 – 2027-12-31 · Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
What this study did
Other / comorbidity
NCT06229912 · M.D. Anderson Cancer Center
2024-06-04 – 2028-12-01 · Leukemia, HOX Gene
What this study did
Phase 1/2 (6)
Acute Lymphoblastic Leukemia
NCT07356154 · Memorial Sloan Kettering Cancer Center
2026-01-16 – 2029-01-16 · Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
What this study did
Acute Myeloid Leukemia
NCT06284486 · M.D. Anderson Cancer Center
2024-09-23 – 2028-12-30 · Acute Myeloid Leukemia
What this study did
NCT05360160 · M.D. Anderson Cancer Center
2022-10-14 – 2026-12-01 · Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07734077 · John Mascarenhas
2026-12-01 – 2028-12-01 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
NCT05731947 · Syndax Pharmaceuticals
2023-04-04 – 2025-06-30 · Colorectal Cancer, Solid Tumors
What this study did
Phase 1 (12)
Acute Lymphoblastic Leukemia
NCT07283640 · M.D. Anderson Cancer Center
2026-11-18 – 2031-08-31 · Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
What this study did
NCT07498465 · Children's Oncology Group
2026-09-10 – 2028-11-12 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
What this study did
NCT06575296 · City of Hope Medical Center
2024-12-31 – 2028-04-29 · Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Leukemia, Childhood Acute Leukemia of Ambiguous Lineage, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
What this study did
NCT05326516 · Syndax Pharmaceuticals
2022-03-09 – 2024-07-29 · Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
What this study did
Acute Myeloid Leukemia
NCT06313437 · Richard Stone, MD
2024-12-06 – 2028-03-02 · Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
What this study did
NCT05886049 · National Cancer Institute (NCI)
2024-06-20 – 2027-12-31 · Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Secondary Acute Myeloid Leukemia
What this study did
NCT06226571 · Syndax Pharmaceuticals
2024-05-21 – 2027-02 · Acute Myeloid Leukemias
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT06177067 · St. Jude Children's Research Hospital
2024-04-19 – 2029-02 · Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
What this study did
NCT06222580 · Uma Borate
2024-02-20 – 2027-02-28 · Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07923071 · Syndax Pharmaceuticals
2026-11 – 2032-01 · Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia
What this study did
NCT07052994 · M.D. Anderson Cancer Center
2026-05-21 – 2026-05-21 · Pediatric Acute Leukemia
What this study did
NCT05406817 · Syndax Pharmaceuticals
2022-08-05 – 2024-11-18 · Acute Leukemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Revumenib: this drugApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
BlinatumomabApprovedMultispecific antibodyCD19 x CD3Weak signal
NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)ApprovedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Ponatinib (ICLUSIG)ApprovedSmall moleculeBCR-ABL (including T315I)Partial signalFeatured results are non-efficacy only in this race
Icovamenib
Phase 2(overall)
Small moleculeMenin
Partial signal(overall)
No reviewed efficacy summary in this indication
ZiftomenibPhase 1/2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Revumenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT05360160 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06284486 · CT.gov ↗
What to watch
2027 (7)
January 2027 (2)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01 · NCT06177067 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01-31 · NCT06222580 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT06226571 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-02 · NCT06313437 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-15 · NCT04065399 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05886049 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT05761171 · CT.gov ↗
What to watch
2028 (4)
April 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-04-29 · NCT06575296 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-07 · NCT07605949 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia MyelofibrosisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07734077 · CT.gov ↗
What to watch
Phase 2Leukemia, HOX GeneRecruiting
Est. primary completion 2028-12-01 · NCT06229912 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-01-16 · NCT07356154 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06 · NCT07211958 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2029-08-31 · NCT07283640 · CT.gov ↗
What to watch
December 2029 (3)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-12-13 · NCT06652438 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07686107 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07949370 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 1Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed LeukemiaNot yet recruiting
Est. primary completion 2030-01 · NCT07923071 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-04-16 · NCT07636564 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2031-06 · NCT07563010 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-12 · NCT03013998 · CT.gov ↗
What to watch

See the full readout calendar ↗